VivoSeq
Ophthalmology

Presbyopia

20

Pipeline Programs↗

3

Active Trials↗

13

Companies Involved↗

Presbyopia is an emerging landscape with 20 programs across 13 companies. The most active players are Corxel Pharmaceuticals, Taiwan Bio Therapeutics Inc., Orasis Pharmaceuticals Ltd.. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Corxel Pharmaceuticals

2 programs

Phase 1T

Taiwan Bio Therapeutics Inc.

1 program

Phase 1O

Orasis Pharmaceuticals Ltd.

2 programs

Phase 2V

Visus Therapeutics

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2F

Falcon

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

41

clinical trials

Completed32 · 78%
Unknown status3 · 7%
Recruiting2 · 5%
Terminated2 · 5%
Withdrawn1 · 2%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

41 trials

Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
Recruiting·ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.·Phase 2·NCT06948357·119 enrolled
Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A Randomized Clinical Study
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Preclinical·NCT07512089·100 enrolled
Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia
Not yet recruiting·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 3·NCT06451666·330 enrolled
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
Completed·OOrasis Pharmaceuticals Ltd.·Phase 3·NCT04599972·304 enrolled
A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
Completed·AbbVie logoAbbVie·Phase 2·NCT02780115·151 enrolled
A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia
Completed·OOrasis Pharmaceuticals Ltd.·Phase 2·NCT03885011·166 enrolled
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Completed·VVisus Therapeutics·Phase 3·NCT05135286·629 enrolled
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
Completed·AbbVie logoAbbVie·Phase 2·NCT02197806·65 enrolled
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Completed·LLENZ Therapeutics, Inc·Phase 2·NCT02554396·20 enrolled
Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Completed·VVisus Therapeutics·Phase 2·NCT04774237·18 enrolled
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
Completed·GGlaukos Corporation·Phase 2·NCT05124275·123 enrolled
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
Completed·Novartis logoNovartis·Phase 2·NCT03809611·125 enrolled
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Completed·LLENZ Therapeutics, Inc·Phase 1·NCT05936489·30 enrolled
A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
Completed·AbbVie logoAbbVie·Phase 3·NCT03857542·427 enrolled
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Completed·LLENZ Therapeutics, Inc·Phase 3·NCT05728944·229 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)